Swiss researchers have developed a gel capable of inhibiting vessel occlusion after vascular bypass operation
Coronary or peripheral bypasses are the most frequently performed vascular operations. Although one million patients per year and around the world, undergo this intervention, its failure rate reaches 50%, because of poor vessel healing, leading to vessel graft occlusion.
Credit: © UNIGE
To improve the outcome of bypasses, researchers from the University of Geneva (UNIGE) work together with medical doctors from the Lausanne University Hospital (CHUV). They developed a gel containing microparticles -'GeM', enabling the controlled release of a drug inhibiting cellular over-proliferation.
Administered locally, directly on the bypass graft during surgery, this preventive treatment will reduce the risk of obstruction reoccurrence. This research can be read in The Journal of Controlled Release.
The vascular bypass allows a blocked artery to be bypassed by implanting a vessel removed from the patient, and this is done in order to create a deviation in circulation. However, in 50% of cases, excessive vascular cell proliferation, called hyperplasia, occurs around the suturing site of the transplanted vessel.
Hyperplasia then leads to a decrease in blood flow within five years following the operation, requiring a new surgery. Today, doctors prescribe atorvastatin (ATV) orally against hyperplasia. However, this route of administration is not adapted to this pathology.
This is why Doctor François Saucy's team from CHUV joined forces with Florence Delie and Olivier Jordan, researchers at the Department of Pharmaceutical Sciences at UNIGE Faculty of Science. The goal: to find a way for local administration of ATV, that will remain available over a long time period, in order to overcome the disadvantages of high dosage taken orally.
'We immediately thought of a gel mixed with ATV, being directly applied on the vessel during surgery. Being viscous, it remains in place and enables local release, explains Florence Delie. 'But, we had an important challenge- doctors recommended the presence of the drug over a period of four weeks to avoid hyperplasia development, while the gel is only effective for three days'.
Researchers from UNIGE have consequently added polymer microparticles containing ATV to the original formulation. These microparticles carry the encapsulated drug and gradually dissolve into the gel, therefore releasing ATV over one month.
The right dose in the right place
'It is about a controlled release system: the right dose at the right place, with the correct release profile, emphasises Olivier Jordan. 'We discovered that this formulation only works using the combination of, on one side, quickly released ATV mixed into the gel and on the other side, the microparticles, which act over the long term. There lies our innovation', adds Ioanna Mylonaki, researcher at UNIGE. 'Its use on patients is contemplated in five to ten years. Its efficacy would revolutionize the success rate of vascular bypasses.'
Florence Delie | EurekAlert!
Gentle sensors for diagnosing brain disorders
29.09.2016 | King Abdullah University of Science and Technology
New imaging technique in Alzheimer’s disease - opens up possibilities for new drug development
28.09.2016 | Lund University
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences